Producing A Successful Malaria Vaccine: Innovation In The Lab And Beyond

Abstract

With approximately 225 million new cases and 800,000 deaths annually, malaria exacts a tremendous toll--mostly on African children under the age of five. Late-stage trials of an advanced malaria vaccine candidate--which, if approved, would become the world's first malaria vaccine--are under way, and it may be ready for use by 2015. This article recounts the pivotal roles in that achievement played by collaborations of nonprofit organizations, pharmaceutical companies, private and public donors, and countries whose citizens would benefit most directly from a vaccine. Just as it takes a village to raise a child, it has taken a huge number of stakeholders around the world to reach this point. Developing even more effective vaccines for malaria and other diseases will require continued hard work and creative thinking from scientists, regulators, and policy makers.

With a little help from my friends

“…Three articles on inter-organizational networks focused on a particular problem and presented multi-sector collaboration as a way to address the problem. For example, Loucq et al (2011) discuss the necessity of creating and providing the world's first malaria vaccine and the collaboration required by private scientists, universities, distributors, and government entities to make such a vaccine a reality. Similarly, Arends-Kuenning and Makundi (2000) discuss the necessity of multiple-sector collaboration to ensure that crop yields aided by biotechnology are made available to developing countries in order to benefit the poor.…”